Natural history and prognosis of pancreatic endocrine tumors;Histoire naturelle et pronostic des tumeurs endocrines du pancréas

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 3 SUPPL., 2003, Pages

  Ruszniewski, Philippe ^a,c   Terris, Benoît ^b  

^a Service de Gostroenterologie   (France)

^b Service d'Anotomie Pothologique   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLINE; HERMES ANTIGEN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER GRADING; CANCER RISK; CELL PROLIFERATION; CELL SIZE; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; ENDOCRINE TUMOR; EVALUATION; FLOW CYTOMETRY; GASTRINOMA; HUMAN; MALIGNANT TRANSFORMATION; PANCREAS CARCINOMA; PANCREAS ISLET CELL CARCINOMA; PANCREAS TUMOR; PROGNOSIS; TUMOR DIFFERENTIATION; CARCINOMA; PATHOLOGY; REVIEW;

CARCINOMA; ENDOCRINE GLAND NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038340237     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988;183:155-68.
2. Capella C, Heitz PU, Hötfler, Solcia E, Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Archiv 1995;425:547-60.
3. Gentil Perret A, Mosnier JF, Buono JP, Berthelot P, Chipponi J, Balique JG et al. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 1998; 109:286-93.
4. Cubilla AL, Hajdu SI. Islet cell carcinoma of the pancreas. Arch Pathol 1975;99:204-7.
5. Kenny BD, Sloan JM, Hamilton PW, Watt PC, Johnston CF, Buchanan KD. The role of morphometry in predicting prognosis in pancreatic islet cell tumors. Cancer 1989;64:460-5.
6. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998;43:422-7.
7. Stabile BE, Passaro E. Benign and malignant gastrinoma. Am J Surg 1984;149:144-9.
8. Zollinger RM. Gastrinoma: factors influencing prognosis. Surgery 1984;97:49-54.
9. Vallot T, Mignon M, Lewin MJM, Bonfils S. Endocrinologie disgestive pratique. Bases cliniques et théoriques. 1996, John Libbey Eurotext, Paris.
10. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996;429:323-33.
11. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317:1699-701.
12. Heymann MF, Joubert M, Nemeth J, Franc B, Visset J, Hamy A et al. Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology 2000;36:421-32.
13. Hobbs RD, Stewart AF, Ravin ND, Carter D. Hypercalcemia in small cell carcinoma of the pancreas. Cancer 1984;53:1552-4.
14. Ibrahim NB, Briggs JC, Corbishley CM. Extrapulmonary oat cell carcinoma. Cancer 1984;54:1645-61.
15. Delcore R, Friesen SR. Other rare tumors of the endocrine pancreas. In: Surgical diseases of the pancreas. Howard JM, Idezuki I, Ishe I, Prinz RA Eds. Williams and Wilkins Publishers, 3rd Edition, 1998;789-815.
16. Jereczek B, Jassem J, Karnicka-Mlodkowska H, Badzio A, Mos-Antkowiak R, Szczepek B et al. Autopsy findings in small cell lung cancer. Neoplasma 1996;43:133-7.
17. Mignon M, Jaïs P, Cadiot G, Ben Yedder D, Vatier J. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas: recent advances in research and management. Basel: Karger. Front Gastrointest Res 1995;23:223-39.
18. Solcia E, Capella C, Klöppel G. Tumors of the pancreas. AFIP Atlas of Tumor Pathology, third series, fascicle 20. Washington DC: Armed Forced Institute of Pathology, 1997.
19. Ruszniewski P, Podevin P, Cadiot G, Marmuse JP, Mignon M, Vissuzaine C, Bonfils S, Lehy T. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 1993;8:295-304.
20. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995;108:1637-49.
21. Ellison EC. Forty-year appraisal of gastrinoma. Back to the future. Ann Surg 1995;222:511-21.
22. Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM) and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999;116:286-93.
23. Jensen RT. Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF, eds. Recent advances in the pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors. Montrouge: John Libbey Eurotext 1999;192-219.
24. von Herbay A, Sieg B, Schürmann, Hofmann WJ, Betzler M, Otto HF. Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gut 1991;32:949-53.
25. Guinebretière JM, Sabourin JC. Ki-67, marqueur de prolifération. Ann Pathol 1997;17:25-30.
26. Costes V, Marty-Ane C, Picot MC, Serre I, Pujol JL, Mary H, Baldet P. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and Ki-67-labeling study. Hum Pathol 1995;26:740-5.
27. Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in pheochromocytoma. Hum Pathol 1998;29:522-6.
28. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996;27:1124-34.
29. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992;13:27-35.
30. Bordi C, Viale G. Analysis of cell proliferation and tumor antigens of prognostic significance in pancreatic endocrine tumors; in Mignon M, Jensen RT (eds): Endocrine tumors of the pancreas, Front Gastrointest Res. Basel, Karger, 1995;23:45-59.
31. Padberg BC, Woenckhaus J, Hilger G, Beccu L, Jochum W, Range U et al. DNA cytophotometry and prognosis in typical and atypical bronchopulmonary carcinoids. A clinicomorphologic study of 100 neuroendocrine lung tumors. Am J Surg Pathol 1996;20:815-22.
32. Metz DC, Kuchnio M, Fraker DL, Venzon DJ, Jaffe G, Jensen RT et al. Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. Gastroenterology 1993;105:799-813.
33. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-52.
34. Wang DG, Johnston CF, Buchanan KD. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer 1997;80:668-75.